To evaluate the combined treatment with heteronemin and tetrac, we further determined the effects of their combination in HT-29 cells (KRAS WT CRC) and HCT-116 cells (KRAS MT CRC) using flow cytometry. Here, KRAS is linked to colorectal carcinoma.